[1]DURAISINGHAM S S, BUCKLAND M S, GRIGORIADOU S,et al. Secondary antibody deficiency[J]. Expert Rev Clin Immunol,2014,10(5):583-591.
[2]RUGGIERO A, BATTISTA A, COCCIA P,et al. How to manage vaccinations in children with cancer[J]. Pediatr Blood Cancer,2011,57(7):1104-1108.
[3]ESPOSITO S, CECINATI V, SCICCHITANO B, et al.Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy[J]. Vaccine ,2010,28(6):1558-1565.
[4]ESPOSITO S, MASTROLIA M V, PRADA E, et al. Vaccine administration in children with chronic kidney disease[J]. Vaccine,2014,32(49):6601-6606.
[5]STRANGFELD A, LISTING J, HERZER P,et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents[J]. JAMA,2009,301(7):737-744.
[6]PRINCIPI N, ESPOSITO S. Vaccine use in primaryimmunodeficiency disorders[J]. Vaccine,2014,32(30):3725-3731.
[7]MOIR S, FAUCI A S. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease[J]. J Allergy Clin Immunol,2008,122(1):12-19.
[8]PENSIEROSO S, CAGIGI A, PALMA P, et al. Timing ofHAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children[J]. Proc Natl Acad Sci USA ,2009,106(19):7939-7944.
[9]ESPOSITO S, TAGLIAFERRI L, DALENO C, et al. Pandemicinfluenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents[J]. Vaccine,2011,29(8):1677-1682.
[10]TANZI E, ESPOSITO S, BOJANIN J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy[J]. J Med Virol,2006,78(4):440-445.
[11]ABZUG M J, PELTON S I, SONG L Y, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy[J]. Pediatr Infect Dis J,2006,25(10):920-929.
[12]LUJAN-ZILBERMANN J, WARSHAW M G, WILLIAMS P L, et al.Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus[J]. J Pediatr,2012,161(4):676-681.
[13]TANGSINMANKONG N, KAMCHAISATIAN W, DAY N K, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy[J]. Ann Allergy Asthma Immunol,2004,92(5):558-564.
[14]CHING N, DEVILLE J G, NIELSEN K A, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART)[J]. Eur J Pediatr,2007,166(1):51-56.
[15]CAGIGI A, COTUGNO N, GIAQUINTO C, et al. Immunereconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions[J]. Hum Vaccin Immunother,2012,8(12):1784-1794.
[16]STICCHI L, BRUZZONE B, CALIGIURI P, et al. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients[J]. Hum Vaccin Immunother,2014,11(1):263-269.
[17]FARQUHAR C, WAMALWA D, SELIG S, et al. Immuneresponses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination[J]. Pediatr Infect Dis J ,2009,28(4):295-299.
[18]PRINCIPI N, ESPOSITO S. The present and future of tuberculosis vaccinations[J]. Tuberculosis (Edinb) ,2015,95(1):6-13.
[19]ESPOSITO S, CECINATI V, BRESCIA L, et al. Vaccinations in children with cancer[J]. Vaccine ,2010,28(19):3278-3284.
[20]MACKALL C L. T-cell immunodeficiency following antineoplastic therapy: a review[J]. Stem Cells,2000,18(1):10-18.
[21]PATEL S R, ORTIN M, COHEN B J, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia[J]. Clin Infect Dis,2007,44(5):635-642.
[22]KOSMIDIS S, BAKA M, BOUHOUTSOU D, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL[J]. Pediatr Blood Cancer,2008,50(3):528-532.
[23]LUTHY K E, TIEDEMAN M E, BECKSTRAND R L, et al. Safety of live-virus vaccines for children with immune deficiency[J]. J Am Acad Nurse Pract ,2006,18(10):494-503.
[24]GANGAPPA S, KOKKO K E, CARLSON L M, et al. Immune responsiveness and protective immunity after transplantation[J]. Transpl Int,2008,21(4):293-303.
[25]LJUNGMAN P, CORDONNIER C, EINSELE H, et al. Vaccination of hematopoietic cell transplant recipients[J]. Bone Marrow Transplant,2009,44(8):521-526.
[26]VANCE E, GEORGE S, GUINAN E C, et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation[J]. Bone Marrow Transplant,1998,22(8):735-741.
[27]SMALL T N, ZELENETZ A D, NOY A, et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine(Tdap) after autologous peripheral blood stem cell transplantation[J]. Biol Blood Marrow Transplant,2009,15(12):1538-1542.
[28]SHETTY A K, WINTER M A. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation[J]. Ochsner J,2012,12(3):228-243.
[29]RUBIN L G, LEVIN M J, LJUNGMAN P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host[J]. Clin Infect Dis,2014,58(3):309-318.
[30]KUSSMAUL S C, HORN B N, DVORAK C C, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs[J]. Bone Marrow Transplant,2010,45(11):1602-1606.
[31]DANZINGER-ISAKOV L, KUMAR D,AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients[J]. Am J Transplant,2009,9 (suppl 4): S258-262.
[32]LADD J M, KARKAZIS K, MAGNUS D. Parental refusal of vaccination and transplantation listing decisions: a nationwide survey[J]. Pediatr Transplant,2013,17(3):244-250.
[33]ABUALI M M, ARNON R, POSADA R. An update on immunizations before and after transplantation in the pediatric solid organ transplant recipient[J]. Pediatr Transplant,2011,15(8):770-777.
[34]DAVIES K, WOO P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence[J]. Rheumatology ,2002,41(8):937-941.
[35]DELL'ERA L, ESPOSITO S, CORONA F, et al. Vaccination of children and adolescents with rheumatic diseases[J]. Rheumatology(Oxford),2011,50(8):1358-1365.
[36]WESTRA J, VAN ASSEN S, WILTING K R, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients[J]. Clin Exp Immunol,2014,178(1):40-47.
[37]SHEARER W T, FLEISHER T A, BUCKLEY R H,et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts[J]. J Allergy Clin Immunol ,2014,133(4):961-966.
[38]World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia[J]. J Infect Dis,1995,171(5):1097-1106.
